CellinCells clinical trials
CellinCells is the lead sponsor of 3 current clinical trials in our South Korea register. 2 are recruiting patients now. The most common phase is Observational. The most-studied condition is Atrophic Scar.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by CellinCells
3 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
CIC101-02-LT is a Long-term Follow-up Study of Participants Treated With TRTP-101 and Will Evaluate the Long-term Safety and Efficacy of TRTP-101.
NCT07892937 · ClinicalTrials.gov ↗ · Atrophic Scar
|
Observational | Recruiting | 2026-09 | South Korea |
|
Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars
NCT07474467 · ClinicalTrials.gov ↗ · Atrophic Scar
|
Phase 1/2 | Recruiting | 2026-08 | South Korea |
|
Long-Term Follow-up of Adult With Atorpphic Scars Treated With TRTP-101
NCT06435884 · ClinicalTrials.gov ↗ · Atrophic Scar
|
Observational | Active, closed | 2024-09 | South Korea |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Conditions in CellinCells trials
1 conditionBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in South Korea | 3 | 2 |
A trial with sites in more than one country appears in each of those registers.
Questions about CellinCells trials
How many clinical trials does CellinCells sponsor?
CellinCells is the lead sponsor of 3 current trials on ClinicalTrials.gov in our South Korea register, as of the registry sync on 29 October 2026. Completed and withdrawn studies are not counted.
Are CellinCells trials recruiting?
Yes. 2 of its 3 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 29 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.